Self-Referral Rules Finalized by HCFA

Publication
Article
OncologyONCOLOGY Vol 15 No 3
Volume 15
Issue 3

Oncologists who have a financial interest in-or are thinking about investing in-a related business that provides such things as magnetic resonance imaging, computed tomography, or radiology services should pay attention to the final rules from the

Oncologists who have a financial interest in—or are thinkingaboutinvesting in—a related business that provides such things as magnetic resonance imaging, computed tomography, or radiology services should payattention to the final rules from the Health Care Financing Administration(HCFA) on "self-referral." The good news is that the final rules aresubstantially preferable to the rules that HCFA proposed in 1998. In general, aphysician cannot refer a Medicare or Medicaid patient for any of 10 listedservices if he or any of his immediate family has a financial interest in thatfacility.

William Jessee, MD, CMPE, president of the Medical GroupManagement Association, said his group is "pleased that HCFA has includedseveral important changes in the long-awaited Stark II physician self-referralrules." Stark refers to Rep. Pete Stark (D-Calif), who is responsible forputting these restrictions into law. Among the "important changes"referred to by Dr. Jessee are creation of a new exemption for indirectcompensation agreements, expansion of the in-office ancillary servicesexception, and creation of a new exception for compensation of faculty inacademic medical centers. HCFA also changed the way it will define "grouppractices," making it easier for groups to qualify as a "single legalentity" and giving them more wiggle room in terms of the self-referralrules.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content